drugset

drugset / Trial / NCT06196905

An Exploratory Study of MT-2990 in Patients With AAV

NCT06196905 ↗

Phase 1 Completed 5 enrolled Tanabe Pharma Corporation

NaSingle-groupOpen-labelTreatment

Summary

To explore the efficacy, safety, pharmacokinetics and mechanism of action of MT-2990 in patients with AAV.

Timeline

Start: 2024-06-24
Primary completion: 2026-01-14
Completion: 2026-01-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MT-2990	Unknown	—	Intravenous

Indications